Characteristic

N (%)

Age

Median

65

Range

41 - 86

<75

60 (83.3)

Male

47 (65.3)

Race

White

37 (51.4)

Black

30 (41.7)

Other

3 (4.2)

ECOG PSa

0

26 (36.1)

1

36 (50)

2

10 (13.9)

3

0 (0)

Smoking historyb

Light/never

18 (25)

Heavy

51 (70.8)

Histology

Non-squamous

57 (79.2)

Squamous

15 (20.8)

Targetable driver mutationc

EGFR

9 (12.5)

ALK

0

ROS-1

0

Site of metastases at initiation of therapy

Bone

20 (27.8)

Liver

13 (18.1)

Brain

11 (15.3)

Line of therapy

2

36 (50)

3

20 (27.8)

4+

9 (12.5)

Therapy

Nivolumab

54 (75)

Pembrolizumab

18 (25)

dNLR

<3

55 (76.4)

≥3

17 (23.6)